Company environment · Sterile injectable quality · NMPA / CDE
Sterile oncology injectable China NMPA / CDE review
Under NMPA / CDE review; 80-day deficiency response and pre-approval GMP inspection readiness.
1What does this company do?
Sterile injectable manufacturer responding to a China NMPA / CDE supplementary-data deficiency notice ahead of a pre-approval dynamic GMP inspection.
2Where is the product on its way to patients?
Sterile small-molecule oncology injection in glass vials under China CDE deficiency review.
- 1Discovery & Lead Selection
- 2IND-Enabling Nonclinical
- 3Clinical Development (IND / CTA)
- 4Registration & Dossier Review
- The product is here
- 5Approval & Launch Readiness
- 6Commercial Lifecycle & GMP
3What is happening right now?
The statutory 80-day CDE deficiency clock is active, with an on-site registration inspection scheduled.
4Tasks
4 tasks in the 81-task Biopharma Bench V0.2 suite, graded against expert rubric criteria.
Sealed partner records & open showcases
This environment is reconstructed from a confidential drug or device program, so its records, tasks, and rubrics remain sealed.
To inspect complete workspaces, candidate deliverables, trajectories, and rubric criteria end to end, open the two public companion showcases:
Havenor Therapeutics (synthetic sterile-injectables CMC/MSAT) →
Broad Institute (public FDA CDER IND 167326 record) →